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Breast cancer is one of the representative diseases for which 
the molecular classification is based on the profile of gene ex-
pression in addition to the conventional histological grade. Its 
molecular classifications include luminal A, luminal B, human 
epidermal growth factor receptor 2 (HER-2), basal-like and nor-
mal-like types.1,2 Based on a gene clustering analysis, Farmer et 
al.3 separately described the molecular apocrine breast cancer 
(MABC). The MABC accounts for 8-14% of total cases of breast 
cancer and it is characterized by the apocrine histology, andro-
gen receptor (AR) positivity, estrogen receptor (ER) negativity 
and presence outside the basal-like subtypes. Furthermore, HER-
2 amplification is frequently found. The MABC is thought to 
be associated with a poor long-term survival. Although it is de-
fined by a gene clustering analysis, there are specific surrogate 
immunohistochemical markers such as AR and gamma-gluta-
myltrasferase 1 (GGT1).3,4 MABC is one of the subtypes of breast 
cancer based on its molecular classification, little is known about 
its clinicopathologic characteristics as compared with other mo-
lecular subtypes such as luminal type, HER-2 type or basal-like 
type. 
Given the above background, we conducted this study to elu-
cidate the clinicopathologic features and their implications on 
the immunohistochemistry (IHC) in cases of MABC.
MATERIALS AND METHODS
Patient selection and clinicopathologic analysis
The current study enrolled patients who had been diagnosed 
with invasive ductal carcinoma at Severance Hospital during the 
year of 2001. Exclusion criteria include patients who underwent 
preoperative neoadjuvant treatment as hormonal therapy, che-
motherapy, and radiotherapy. The current study was approved 
by the Institutional Review Board (IRB) of Severance Hospital. 
A total of 204 patients were enrolled in the current study, who 
submitted a written informed consent. Representative hema-
toxylin and eosin (H&E)-stained slides from each patient were 
retrospectively reviewed by two pathologists (YJC and JSK). 
Histologic grade was estimated using the Nottingham grading 
system.5 Apocrine histology was evaluated from H&E-stained 
slides, which was defined by such histopathologic findings as 
abundant granular eosinophilic cytoplasm, cytoplasmic vacuol-
ization and vesicular nuclei with prominent nucleoli in more 
than 10% of tumor cells.6 Tumor staging was done based on 
the 7th American Joint Committee on Cancer (AJCC) criteria.7 
Disease-free survival (DFS) was calculated from the date of the 
first curative surgery to that of the first loco-regional or system-
ic relapse, or death without any type of relapse. Overall survival 
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(OS) was estimated from the date of the first curative operation 
to that of the last follow-up or death from any cause. Clinical 
parameters include age at initial diagnosis, lymph node status, 
local recurrence, systemic recurrence, and patient survival. 
Tissue microarrays
Representative invasive tumor areas were selected from the 
whole H&E-stained tumor slides. Corresponding spots were 
marked on the surface of the paraffin block. The selected area 
was punched out with a tissue extractor. In addition, a 3-mm 
tissue core was placed into a 6×5 recipient block. More than 
two tissue cores were extracted to minimize the extraction bias. 
Each tissue core was assigned with a unique tissue microarray 
location number that was linked to a database containing other 
clinicopathologic data.
Immunohistochemistry (IHC)
The antibodies and dilution used for IHC are shown in Table 
1. Formalin-fixed, paraffin-embedded tissue sections from the 
tissue microarray were prepared for the IHC. The 3-mm sec-
tions were deparaffinized in xylene and rehydrated through a 
graded alcohol series to distilled water. The slides were subject-
ed to antigen retrieval by a microwave irradiation and then in-
cubated with primary antibodies. Binding was detected with 
biotinylated anti-mouse immunoglobulin, followed by peroxi-
dase-labeled streptavidin with 3,3´-diaminobenzidine chromo-
gen as the substrate. Optimal primary antibody incubation times 
and concentrations were determined by serial dilution for each 
immunohistochemical assay using a tissue block fixed and em-
bedded exactly as for the experiments. Slides were counterstain-
ed with Harris hematoxylin, for which two pathologists inter-
preted the staining using a multi-view microscope. 
Interpretation of IHC
All immunohistochemical markers were assessed on light 
microscopy. Slides were scored according to the percentage of 
labeled tumor cells exhibiting nuclear (ER and AR), cytoplas-
mic (GGT1 and cytokeratin [CK] 5/6) and membranous (HER-
2 and epidermal growth factor receptor [EGFR]) staining. The 
ER IHC was considered positive when more than 1% of the in-
vasive tumor cells showed ER expression.8 The HER-2 staining 
was scored according to the American Society of Clinical On-
cology (ASCO)/College of American Pathologists (CAP) guide-
lines based on the grading system: 0, no immunostaining; 1+, 
weak incomplete membranous staining in any percentage of the 
tumor cells; 2+, complete membranous staining, either non-
uniform or weak in at least 10% of tumor cells; and 3+, uni-
form intense membranous staining in >30% of tumor cells. 
Specimens with 0 to 1+ were regarded as negative and those 
with 3+ were considered positive.9 Results for CK5/6, EGFR, 
AR, and GGT1 were considered positive when more than 1% 
of the tumor cells were stained.
Fluorescence in situ hybridization (FISH) analysis
Cases of HER-2 with a staining grade of 2+ on the IHC were 
further tested on the FISH analysis to detect the HER-2 gene 
amplification. Prior to this, invasive tumors were examined on 
the H&E stained slides. This was followed by the FISH analysis 
of the invasive tumor cells using a PathVysion HER-2 DNA 
Probe Kit (Vysis, Downers Grove, IL, USA) according to the 
manufacturer’s instructions. The HER-2 gene copy number was 
counted using an epifluorescence microscope (Olympus, Tokyo, 
Japan) on each slide. At least 60 nuclei of the tumor cells were 
examined to count the number of HER-2 and chromosome 17 
signals. According to the ASCO/CAP guidelines,9 if the absolute 
HER-2 gene copy number was <4 or the HER-2 gene/chromo-
Table 1. Clone, dilution, and source of antibodies
Antibody Clone Dilution Company
Phenotype-related
ER SP1 1:100 Thermo Scientific, Fremont, CA, USA
HER-2 Polyclonal 1 :1,500 Dako, Glostrup, Denmark
Basal-like related
Cytokeratin 5/6 D5/16B4 1:50 Dako, Glostrup, Denmark
EGFR EGFR.25 1:50 Novocastra, Newcastle, UK
Molecular apocrine related
Androgen receptor AR441 1:50 Dako, Glostrup, Denmark
GGT1 IgG2A 1:50 Abcam, Cambridge, UK
Proliferation related
Ki-67 MIB-1 1:150 Dako, Glostrup, Denmark
ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; GGT1, gamma-glutamyltrasferase 1.
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some 17 copy number ratio (HER-2/Chr17 ratio) was <1.8, 
this was considered a lack of the HER-2 amplification. But if 
the absolute HER-2 copy number was 4-6 or the HER-2/Chr17 
ratio was 1.8-2.2, this was considered to show an equivocal am-
plification of HER-2. Finally, if the absolute HER-2 copy num-
ber was >6 or the HER-2/Chr17 ratio was >2.2, this was con-
sidered HER-2 amplified. 
Phenotypic classification of the breast cancer
In the current study, we divided the phenotypes of breast can-
cer into the subtypes based on the molecular classification and 
these include the luminal A type, ER positive and HER-2 neg-
ative; luminal B type, ER positive and HER-2 overexpressed; 
HER-2 overexpressed type, ER negative and HER-2 overex-
pressed; and triple-negative breast cancer (TNBC) type, ER and 
HER-2 negative. TNBC types were subdivided into the basal-
like subtype (CK5/6 and/or EGFR positive) and non-basal-like 
subtype (CK5/6 and EGFR negative). Separate from molecular 
subtypes, we classified the phenotypes of breast cancer, based on 
the expressions of ER and MABC markers,3 into the luminal 
type, ER positive and AR and/or GGT1 positive; basal type, 
ER, AR and GGT1 negative; non-basal type, ER positive and 
AR and GGT1 negative; and MABC type, ER negative and 
AR and/or GGT1 positive. 
Statistical analysis
Statistical analysis was done using SPSS ver. 12.0 (SPSS Inc., 
Chicago, IL, USA). Continuous and categorical variables were 
analyzed using Student’s t-test and Fisher’s exact test, respec-
tively. Statistical significance was set at p<0.05. Kaplan-Meier 
analysis and log-rank statistics were used to evaluate both the 
time to tumor recurrence and overall survival. Multivariate re-
gression analysis was performed using a Cox proportional haz-
ards model.
Table 2. Clinicopathologic characteristics of patients according to the molecular subtype of breast cancer
Parameters 
Total 
(n=204) 
Luminal A 
(n=102) 
Luminal B 
(n=17) 
HER-2 type 
(n=27) 
TNBC (n=58) 
p-value
Basal-like (n=25) Non-basal (n=33) 
Age (yr) 0.089
  ≤35 17 (8.3) 7 (6.9) 0 (0) 1 (3.7) 4 (16.0) 5 (15.2)
  >35 187 (91.7) 95 (93.1) 17 (100) 26 (96.3) 21 (84.0) 28 (84.8)
T stage 0.837
  T1 65 (31.9) 34 (33.3) 5 (29.4) 7 (25.9) 8 (32.0) 11 (33.3)
  T2 128 (62.8) 61 (59.8) 11 (64.7) 18 (66.7) 17 (68.0) 21 (63.6)
  T3 11 (5.4) 7 (6.9) 1 (5.9) 2 (7.4) 0 (0) 1 (3.0)
N stage 0.770
  N0 109 (53.4) 52 (51.0) 8 (47.1) 14 (51.9) 18 (72.0) 17 (51.5)
  N1 60 (29.4) 32 (31.4) 4 (23.5) 7 (25.9) 5 (20.0) 12 (36.4)
  N2 19 (9.3) 10 (9.8) 2 (11.8) 3 (11.1) 1 (4.0) 3 (9.1)
  N3 16 (7.8) 8 (7.8) 3 (17.7) 3 (11.1) 1 (4.0) 1 (3.0)
TNM stage 0.433
  Stage 1 44 (21.6) 24 (23.5) 2 (11.8) 4 (14.8) 7 (28.0) 7 (21.2)
  Stage 2 122 (59.8) 57 (55.9) 10 (58.8) 17 (63.0) 16 (64.0) 22 (66.7)
  Stage 3 38 (18.6) 21 (50.9) 5 (29.4) 6 (22.2) 2 (8.0) 4 (12.1)
Histologic grade 0.000
  I 26 (12.8) 20 (19.6) 2 (11.8) 1 (3.70) 1 (4) 2 (6.06)
  II 111 (54.4) 63 (61.8) 12 (70.6) 11 (40.7) 10 (40.0) 15 (45.5)
  III 67 (32.8) 19 (18.6) 3 (17.7) 15 (55.6) 14 (56.0) 16 (48.5)
Apocrine histology 0.003
  No 164 (80.4) 91 (89.2) 12 (70.6) 16 (59.3) 17 (68.0) 28 (84.9)
  Yes 40 (19.6) 11 (10.8) 5 (29.4) 11 (40.7) 8 (32.0) 5 (15.2)
Ki-67 0.000
  <10% 165 (80.9) 95 (93.1) 17 (100) 19 (70.4) 15 (60.0) 19 (57.6)
  10-30% 23 (11.3) 4 (3.9) 0 (0) 5 (18.5) 6 (24.0) 8 (24.2)
  >30% 16 (7.8) 3 (2.9) 0 (0) 3 (11.1) 4 (16.0) 6 (18.2)
Tumor recurrence 28 (13.7) 13 (12.8) 5 (29.4) 5 (18.5) 3 (12.0) 2 (6.1) 0.318
Distant metastasis 19 (9.3) 9 (8.8) 3 (17.7) 5 (18.5) 2 (8.0) 0 (0) 0.167
Duration of follow-up (mo) 112.8 (8.6-140.6) 117.1 (28.6-140.5) 116.4 (21.3-139.4) 101.5 (14.3-140.6) 106.5 (8.6-138.2) 111.6 (20.4-138.2) 0.118
No. of patient deaths 35 (17.2) 13 (12.7) 4 (23.5) 8 (29.6) 4 (16.0) 5 (15.2) 0.184
Values are presented as number (%) or mean (range).
HER-2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; TNM, tumor, node and metastasis.
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RESULTS
Clinicopathologic characteristics according to the molecular 
subtypes of breast cancer
Our series of patients (n=204) were composed of 102 cases 
(50.0%) of luminal A type, 17 cases (8.3%) of luminal B type, 
27 cases (13.2%) of HER-2 type and 58 cases (28.4%) of TNBC 
type. Besides, cases of TNBC type comprised of 25 cases of bas-
al-like type (25/58, 43.1%) and 33 cases of non-basal like type 
(33/58, 56.9%). Clinicopathologic features are shown in Table 
Table 3. Clinicopathologic characteristics of patients according to breast cancer phenotype
Parameters Total (n=204) Luminal (n=18) Basal (n=60) Non-basal (n=100) MABC (n=26) p-value
Age (yr) 0.306
  ≤35 17 (8.3) 2 (11.1) 8 (13.3) 5 (5.0) 2 (7.7)
  >35 187 (91.7) 16 (88.9) 52 (86.7) 95 (95.0) 24 (92.3)
T stage 0.663
  T1 65 (31.9) 6 (33.3) 20 (33.3) 33 (33.0) 6 (23.1)
  T2 128 (62.8) 10 (55.6) 39 (65.0) 61 (61.0) 18 (69.2)
  T3 11 (5.4) 2 (11.1) 1 (1.7) 6 (6.0) 2 (7.7)
N stage 0.507
  N0 109 (53.4) 9 (50.0) 38 (63.3) 50 (50.0) 12 (46.2)
  N1 60 (29.4) 5 (27.8) 13 (21.7) 31 (31.0) 11 (42.3)
  N2 19 (9.3) 1 (5.6) 6 (10.0) 11 (11.0) 1 (3.9)
  N3 16 (7.8) 3 (16.7) 3 (5.0) 8 (8.0) 2 (7.7)
TNM stage 0.784
  Stage 1 44 (21.6) 5 (27.8) 13 (21.7) 21 (21.0) 5 (19.2)
  Stage 2 122 (59.8) 9 (50.0) 38 (63.3) 57 (57.0) 18 (69.2)
  Stage 3 38 (18.6) 4 (22.2) 9 (15.0) 22 (22.0) 3 (11.5)
Histologic grade 0.000
  I 26 (12.8) 4 (22.2) 3 (5.0) 18 (18.0) 1 (3.9)
  II 111 (54.4) 10 (55.6) 26 (43.3) 64 (64.0) 11 (42.3)
  III 67 (32.8) 4 (22.2) 31 (51.7) 18 (18.0) 14 (53.9)
Apocrine histology 0.007
  No 164 (80.4) 17 (94.4) 47 (78.3) 85 (85.0) 15 (57.7)
  Yes 40 (19.6) 1 (5.6) 13 (21.7) 15 (15.0) 11 (42.3)
AR 0.000
  Positive 9 (4.4) 4 (22.2) 0 (0) 0 (0) 5 (19.2)
  Negative 195 (95.6) 14 (77.8) 60 (100) 100 (100) 21 (80.8)
GGT1 0.000
  Positive 43 (21.1) 17 (94.4) 0 (0) 0 (0) 26 (100)
  Negative 161 (78.9) 1 (5.6) 60 (100) 100 (100) 0 (0)
Cytokeratin 5/6 0.000
  Positive 17 (8.3) 0 (0) 13 (21.7) 0 (0) 4 (15.4)
  Negative 187 (91.7) 18 (100) 47 (78.3) 100 (100) 22 (84.6)
EGFR 0.000
  Positive 24 (11.8) 1 (5.6) 15 (25.0) 2 (2.0) 6 (23.1)
  Negative 180 (88.2) 17 (94.4) 45 (75.0) 98 (98.0) 20 (76.9)
HER-2 0.009
  Positive 44 (21.6) 3 (16.7) 18 (30.0) 13 (13.0) 10 (38.5)
  Negative 160 (78.4) 15 (83.3) 42 (70.0) 87 (87.0) 16 (61.5)
Ki-67 0.000
  <10% 165 (80.9) 18 (100) 38 (63.3) 93 (93.0) 16 (61.5)
  10-30% 23 (11.3) 0 (0) 12 (20.0) 4 (4.0) 7 (26.9)
  >30% 16 (7.8) 0 (0) 10 (16.7) 3 (3.0) 3 (11.5)
Tumor recurrence 28 (13.7) 4 (22.2) 8 (13.3) 14 (14.0) 2 (7.7) 0.751
Distant metastasis 19 (9.3) 4 (22.2) 5 (8.3) 8 (8.0) 2 (7.7) 0.359
Duration of follow-up (mo) 112.8 (8.6-140.6) 117.3 (32.1-139.4) 109.2 (14.3-140.3) 116.9  (21.3-140.5) 102.5 (8.6-140.6) 0.155
No. of patient deaths 35 (17.2) 4 (22.2) 12 (20.0) 13 (13.0) 6 (23.1) 0.471
Values are presented as number (%) or mean (range).
MABC, molecular apocrine breast cancer; TNM, tumor, node and metastasis; AR, androgen receptor; GGT1, gamma-glutamyltrasferase 1; EGFR, epidermal 
growth factor receptor; HER-2, human epidermal growth factor receptor 2.
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2. Both the HER-2 type and TNBC type had a higher histolo-
gic grade (p<0.001) and a higher Ki-67 index (p<0.001) than 
other types. The apocrine histology was observed in 19.6% 
(40/204) of total cases, which was notably seen in cases of HER-
2 type and those of basal-like TNBC type (p=0.003).
Clinicopathologic characteristics according to breast 
cancer phenotype
Clinicopathologic features of patients according to breast can-
cer phenotypes are shown in Table 3 and Fig. 1. The apocrine 
histology was the most notable feature found in cases of MABC 
(p=0.007). Compared to other phenotypes, both basal type and 
MABC demonstrated a higher histologic grade (p<0.001), CK-
5/6 positivity (p<0.001), EGFR positivity (p<0.001), HER-2 
positivity (p=0.009), and a higher Ki-67 index (p<0.001). 
Correlation between the molecular subtype and the 
phenotype in cases of breast cancer
Following an analysis of the correlation between the molecu-
lar subtype and the phenotype of breast cancer, the MABC was 
found to comprise 38.4% (10/26) of HER-2 type and 61.5% 
(16/26) of TNBC type (Table 4). Both luminal type and non-
basal type corresponded to the luminal A molecular subtype 
and a majority of basal type were TNBC type (p=0.001).
Comparison of clinicopathologic features according to 
HER-2, basal marker and apocrine histology in cases of 
MABC
There were no significant differences in the clinicopathologic 
features according to the HER-2, basal marker and apocrine 
histology between MABC and other phenotypes of breast can-
cer. There were no significant differences in the DFS and OS 
between the phenotypes of breast cancer (Fig. 2). But higher 
tendency of poor DFS and OS was observed in cases of MABC 
with positivity to the HER-2 expression and negativity to the 
basal markers (Fig. 3).
A
D
B
E
C
GF
Fig. 1. Histologic and immunologic features of molecular apocrine breast cancer (MABC). It shows abundant granular eosinophilic cytoplasm, 
cytoplasmic vacuolization and vesicular nuclei with prominent nucleoli on histology (A). It is negative for estrogen receptor (B), but is also fre-
quently positive for human epidermal growth factor receptor 2 (C), androgen receptor (D) and gamma-glutamyltrasferase 1 (E). The expres-
sion of basal markers such as epidermal growth factor receptor (F) and cytokeratin 5/6 (G) is also occasionally seen in cases of MABC.
Table 4. Correlation between molecular subtype and tumor phe-
notype
Molecular subtype
Breast cancer phenotype
Luminal 
(n=18)
Basal 
(n=60)
Non-basal 
(n=100)
MABC 
(n=26)
Luminal A (n=102) 15   0 87   0
Luminal B (n=17)   3   0 13   0
HER-2 (n=27)   0 18   0 10
TNBC (n=58)   0 42   0 16
MABC, molecular apocrine breast cancer; HER-2, human epidermal growth 
factor receptor 2; TNBC, triple-negative breast cancer.
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DISCUSSION
 
We examined the clinicopathologic features and their impli-
cations on the IHC in cases of MABC. Our results showed that 
the MABC accounted for 12.7% (26/204) of total cases, which 
was similar to a prevalence of 8-14% seen in previous reports.3 
Although the MABC has been previously defined by a gene 
clustering analysis, it was defined based on the immunohisto-
chemical status of the surrogate markers in the current study. It 
was therefore impossible to simply compare the previous re-
ports with our results. According to previous studies, where the 
MABC was defined by a gene clustering analysis, all the cases 
(n=5) showed the positivity for AR and GGT1. GGT1 is con-
sidered to be a more specific marker for MABC. This is because 
expression of GGT1 is found in only 1.5% of non-MABC cases 
but that of AR is seen in 80% of non-MABC cases.4 Our results 
showed that the expression of AR and that of GGT were seen 
in 2.2% (4/178) and 9.6% (17/178) of non-MABC cases, re-
spectively . 
Our results also showed that the MABC, defined based on the 
IHC findings of the AR and GGT1, demonstrated a significant 
correlation with the HER-2 expression (p=0.009) and apocrine 
histology (p=0.007). A variable range of apocrine differentia-
tion was previously found in cases of MABC.3 In the current 
study, however, the apocrine histology was observed in 42.3% 
of total cases of MABC. Presumably, this discrepancy might be 
due to the stricter criteria used in current study for determining 
the apocrine differentiation/histology. In contrast to the obvious 
apocrine histology of classical apocrine carcinoma, apocrine his-
tology is not generally observed in cases of MABC. The term 
“molecular apocrine” has therefore been coined.3 In the same 
context, our results showed that the apocrine histology was seen 
in only about half of the total cases. Besides, similarly to previ-
ous reports that the expression of HER-2 was seen in 20-50% 
of total cases of MABC, it was observed in 38.5% of our series 
of patients.3,4 The molecular mechanism underlying the correla-
tion between HER-2 signaling and MABC remains unclear. 
One hypothesis is that HER-2 stabilizes AR at the protein lev-
el, which is followed by enhancement of androgenic signaling, 
thus revealing the apocrine phenotype in ER-negative and AR-
positive tumor.10 
In the current study, the MABC was associated with basal 
phenotype markers such as CK5/6 and EGFR. According to 
other studies, the expression of EGFR was seen in 60% of total 
cases of MABC.4 Moreover, the apocrine differentiation and ex-
pression of basal markers including CK5/6 and EGFR are fre-
quently observed in the molecular class HER-2 breast cancer.6 
Because Farmer et al.3 showed that MABC significantly over-
laps with HER-2 enriched type by means of Stanford gene clus-
tering analysis, MABC is assumed to be closely related to HER-
2, apocrine histology and basal markers. Further studies are there-
fore warranted to understand the underlying contexts of these 
observations. 
Twenty six cases of MABC in this study were classified into 
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Fig. 2. Disease-free survival and overall survival depending on the phenotypes of breast cancer. MABC, molecular apocrine breast cancer.
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Fig. 3. The prognostic value of the expression of human epidermal growth factor receptor 2 (HER-2) and basal markers in cases of molecu-
lar apocrine breast cancer.
HER-2 (n=10) and TNBC (n=16) subtypes. Luminal B and 
HER-2 subtypes showed HER-2 expression, while the TNBC 
subtype lacked it. Because HER-2 amplification is typically seen 
in cases of MABC, the phenomenon that TNBC consisted of 
61.5% of MABC seemed to be contradictory. As noted above, 
MABC is nearly identical to the HER-2 enriched type when it 
is assessed by Stanford gene clustering analysis.3 However, not 
every HER-2 enriched type exhibits HER-2 overexpression or 
HER-2 amplification. According to a gene clustering analysis, 
60-65% of the HER-2 enriched type lacks HER-2 overexpres-
sion or HER-2 amplification.1,2,4 Therefore, molecular stratifica-
tion of TNBC indicates that 7-14% of TNBC falls into the HER-
2 enriched type/MABC,11 which could explain our findings that 
TNBC comprised some part of MABC. In the current study, 
following an analysis of the subgroups of MABC based on the 
apocrine histology and IHC on HER2, EGFR, CK5/6, despite 
a lack of the statistical significance, higher tendency of poor DFS 
and OS was observed in association with the expression of HER-
2 and the absence of basal markers. Previous studies have shown 
that the MABC had a poorer prognosis than other phenotypes.3,12 
In the current study, however, there were no significant differ-
ences in the prognosis between the MABC and other pheno-
types. Presumably, this discrepancy might be due to the differ-
ence in a patient population between previous reports and our 
results. We retrospectively analyzed data of 204 patients who 
had been diagnosed with invasive ductal carcinoma of the breast 
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at Severance hospital during the year of 2001. These enrolled 
patients had not received neoadjuvant treatment. But other pre-
vious studies have enrolled patients with locally advanced breast 
cancer who underwent neoadjuvant chemotherapy. In addition, 
there were also differences in the methods to define the MABC 
between previous reports and our results. This might also cause 
a selection bias. Furthermore, previous studies have used a gene 
profiling analysis in making a definition of MABC. In the cur-
rent study, however, we used the surrogate IHC markers in de-
fining it. 
There are some limitations of the current study and these in-
clude a smaller number of enrolled patients and a shorter fol-
low-up period. Further studies are therefore warranted in a large 
series of patients with a longer follow-up period.
In conclusion, the MABC is a subtype of breast cancer char-
acterized by apocrine histology accompanied by positivity for 
HER-2 and basal markers such as CK5/6 and EGFR. 
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